1.Interphase FISH of amniocytes in the third trimester
Zeshan YOU ; Jia HUANG ; Jiansheng CHEN
Chinese Journal of Perinatal Medicine 1998;0(01):-
Objective To study the interphase FISH of cells from aminotic fluid in the third trimester prospectively. Methods Amniotic fluid (5ml) was obtained in 32 pregnant women in the third trimester who underwent cordocentesis for karyotyping. FISH was performed on uncultured am niocytes and the results were compared with karyotypes. Results Abnormal aneuploid were identified in 6 cases among the 32 women. The FISH results were consistent with the karyotypes. Conclusions Interphase FISH in third-trimester amniocentesis can provide an accurate clinical diagnosis on common aneupoidies.
2.Selective pregnancy reduction in second trimester
Zeshan YOU ; Qun FANG ; Jiansheng CHEN
Chinese Journal of Perinatal Medicine 1998;0(02):-
Objective To investigate selective pregnancy reduction in second-trimester and its notices. Methods Selective pregnancy reduction in 19 cases of multiple pregnancy during 12~25 gestational age was performed,including 6 cases of twins,1 cases of triplets,1 case of quadruplet and 1 case of sextuplet. Ultrasonographically guided transabdominal intracardiac injection of high concentrate potassium chloride (KCl) solution was used. Results Performances of selective feticide in all twins were successful,except one monochorionic twins. In 11 cases of triplets,one case was aborted,one case was monozygotic triplet. Selective feticide was performed successfully in 7 of the rest 9 cases and the quadruplet Two cases were aborted after the procedure. The sextuplet was aborted after feticide. Conclusion Multifetal pregnancy reduction can be successfully performed in the second trimester without severe maternal complications. But abortion might occur afterwards. It is possible to reduce the abortion rate if monozygotic twin or triplet can be excluded before feticide,choosing the gestational sac which near the fundus,reducing the amniotic fluid volume of the target fetus or postponing feticide.
3.Decreased Expression of Long Non-Coding RNA GAS5 in Ovarian Cancer Patients and Its Clinical Significance
Jie LI ; Yinguang LI ; Aiyue CHEN ; Zhuyu LI ; Wenhui HOU ; Zeshan YOU
Journal of Sun Yat-sen University(Medical Sciences) 2017;38(5):746-751
[Objective]Dysregulated long noncoding RNAs(lncRNAs)have been found involved in human diseases,including cancers. Long non-coding RNA growth arrest-specific 5(GAS5)was reported to be dysregulated in different types of cancers. Howev-er,the role of GAS5 in ovarian cancer remains elusive.[Methods]In the present study,the expression of GAS5 was detected in 108 ovarian cancer tissues and compared adjacent normal tissues by quantitative real-time PCR(qRT-PCR).[Results]The results showed that the expression levels of lncRNA GAS5 were significantly decreased in cancer tissues(P=0.0004),and it was negatively correlated with tumor size(<5 cm vs.>5 cm,P<0.0001),invasion depth(T1-T2 vs. T3-T4,P=0.0021),and tumor grade(Ⅰ~Ⅱgrades vsⅢ~Ⅳgrades,P=0.0086)in ovarian cancer patients. Kaplan-Meier analysis demonstrated that decreased lncRNA GAS5 expression contributed to poor disease-free survival and overall survival.[Conclusion]In conclusion ,our study suggested that decreased lncRNA GAS5 expression may beidentified as a potential poor prognostic biomarker in ovarian cancer.
4.Thyroid Function Change in Pregnant Women with Different Types of Gestational Diabetes Mellitus
Aiyue CHEN ; Jie LI ; Zhuyu LI ; Qin ZHANG ; Li LI ; Shanyang HE ; Zeshan YOU ; Liqun LIU
Journal of Sun Yat-sen University(Medical Sciences) 2017;38(3):443-447
[Objective] To investigate the relationship of different types of gestational diabetes mellitus (GDM) and thyroid function.[Methods] A Total of 3846 cases,which received prenatal examination,delivered in the Eastern Hospital of the First Affiliated Hospital,Sun Yat-sen University and performed a 75 g oral glucose tolerance test (75 g 0GTT) at 24-28 gestational weeks,from Jan 1st,2014 to Dec 31st,2015,were divided into 2 groups.Normal blood glucose group:the result of OGTT (fasting plasma glucose,1 hour glucose and 2 hour glucose) was normal;Gestational diabetes mellitus group (GDM group):the result of 0GTT was abnormal.GDM group were divided into Ⅰ,Ⅱ,and lⅢ.GDM Ⅰ defined as one abnormal blood glucose of result.GDM Ⅱ:two abnormal blood glucose.GDM Ⅲ:three abnormal blood glucose.1868 cases of healthy pregnant women were reselected as the control group.TSH,FT4 and TPO Ab were detected in two groups.Analysis of Variance,Mann-Whitney U test,Kruskal Wallis rank test or Fisher's test was used for statistical analysis.[Result] There were statistically significant difference in TSH,FT4 between GDM subgroup and control group (P =0.012,P =0.002).TSH median trend to increase in GDM Ⅱ,and FT4 median trend to decrease in GDM Ⅱ.The Prevalence of hypothyroidism in GDM Ⅱ and GDM Ⅲ were higher than those in control group.[Conclusion] The GDM group with two or three abnormal blood glucose had a higher incidence thyroid gland dysfunction,especial with subclinical hypothyroidism.We should fully test the thyroid function,treat diabetes as early as possible and improve the pregnancy outcome as we could.
5.Prognostic immune response and drug sensitivity analysis of hepatocellular carcinoma fatty acid metabolism lncRNA based on bioinformatics
Miaodong WANG ; Peichun PENG ; Zeshan CHEN ; Xin DENG
Chinese Journal of Immunology 2024;40(12):2565-2573,中插3
Objective:To explore prognostic lncRNA related with fatty acid metabolism,immune response and drug sensitivity in hepatocellular carcinoma(HCC).Methods:Bioinformatics was used to obtain HCC gene data of TCGA database,most prognostic lncRNA were screened out,and prognostic model was constructed,whose accuracy was verified by ROC curve and nomogram.GO and KEGG were used for biological analysis of lncRNA.GSVA and TMB were used to analyze immune status and mutant genes of HCC patients.TIDE score was used to analyze benefit of immunotherapy in HCC patients to identify potentially effective drugs for HCC.Results:Four lncRNAs(AC074117.1,TMCC1-AS1,LINC01063,MKLN1-AS)related to fatty acid metabolism were identified.K-M curve and ROC curve confirmed that stage and risk score could evaluate prognosis of HCC patients.Nomogram confirmed accuracy of the model prediction;GO and KEGG analysis confirmed abundant biological functions of lncRNA related to fatty acid metabolism.GSVA analysis showed that plasma cells,B cells,neutrophils,NK cells and type Ⅱ-IFN response were significantly different between two risk groups.Patients with low TMB and low risk had the best prognosis.TIDE score of high-risk group was significantly higher than that of low-risk group.Five anticancer drugs more suitable for high-risk population were screened out,namely cyclopamine,rapamy-cin,Proteasome inhibitor,paclitaxel and sunitinib.Conclusion:Prediction model constructed by 4 fatty acid metabolism-related lncRNAs helps to evaluate prognosis of HCC and may provide insights for clinical application and immunotherapy of HCC patients.
6.Health inequity analysis in global burn incidence from 1990 to 2019
Shaobin GUO ; Yanran XU ; Jie CHEN ; Jialong DING ; Zeshan CHEN ; Guina GUO ; Jifeng LI
Chinese Journal of Plastic Surgery 2024;40(11):1206-1214
Objective:To study the regional distribution, temporal trend, and health inequity of burn incidence in the world from 1990 to 2019.Methods:The data related to burns worldwide from 1990 to 2019 were collected from the database of Global Burden of Disease (GBD). Based on the number of burn cases and age-standardized incidence rates, the incidence of burn was observed by age, region, socio-demographic index (SDI) area (divided into 5 categories of SDI areas: high, medium-high, medium, medium-low and low, the higher the area, the higher the degree of social development) and country, all of which were expressed as estimated values. Joinpoint regression analysis of the age-standardized incidence of burns from 1990 to 2019 was performed using Joinpoint 4.8.0.1 software to observe the average annual percentage change (AAPC). Rstudio software was used to analyze the Spearman correlation between the age-standardized incidence of burns and SDI from 1990 to 2019. The global inequities of burn incidence were evaluated using the slope index and concentration index from the health equity assessment toolkit, where the slope index reflected the absolute difference in burn incidence between countries with the lowest and highest SDI, and the concentration index indicated the degree to which burn incidence was concentrated in countries with low or high SDI.Results:From 1990 to 2019, the number of global burncases increased from 8 378 121.71 to 8 955 227.68, with an increase of 6.89%. However, the age-standardized incidence rate of burns showed an overall downward trend, from 149.86/100 000 in 1990 to 117.51/100 000 in 2019, with an AAPC of -0.80%. The incidence of burns in the population aged 10-19 years ranked the first in all age groups during the 30 years. Among the six regions of the world, the number of burn cases and the age-standardized incidence rate of burn in the Americas were the highest in 2019, but these two indexes were lower than those in 1999. In 2019, the number of burn patients in medium SDI areas was the highest, and the number of burn patients in low SDI areas was the lowest. The age-standardized incidence of burns was the highest in high SDI areas, and the lowest in medium-low SDI areas. From 1990 to 2019, the number of patients in high and medium-high SDI areas decreased, and the number of patients in other SDI areas increased. Compared with 1990, the age-standardized incidence rates of burns decreased in all SDI regions in 2019, with the greatest decline seen in high SDI and medium-high SDI regions. Cuba had the highest standardized incidence of burns, while Pakistan had the lowest. Spearman correlation analysis showed that from 1990 to 2019, the age-standardized incidence rates of burns in 204 countries and regions were positively correlated with SDI (all P<0.05), and the correlation coefficient decreased from 0.49 in 1990 to 0.37 in 2019. The health inequality slope index decreased from 212.90/100 000 in 1990 to 59.12/100 000 in 2019, and the concentration index decreased from 21.77% in 1990 to 8.38% in 2019. Conclusion:From 1990 to 2019, the global burn incidence rates are disproportionately concentrated in countries and regions with better development status. A significant reduction in the global burn incidence has been accompanied by a significant reduction in these inequities.
7.Health inequity analysis in global burn incidence from 1990 to 2019
Shaobin GUO ; Yanran XU ; Jie CHEN ; Jialong DING ; Zeshan CHEN ; Guina GUO ; Jifeng LI
Chinese Journal of Plastic Surgery 2024;40(11):1206-1214
Objective:To study the regional distribution, temporal trend, and health inequity of burn incidence in the world from 1990 to 2019.Methods:The data related to burns worldwide from 1990 to 2019 were collected from the database of Global Burden of Disease (GBD). Based on the number of burn cases and age-standardized incidence rates, the incidence of burn was observed by age, region, socio-demographic index (SDI) area (divided into 5 categories of SDI areas: high, medium-high, medium, medium-low and low, the higher the area, the higher the degree of social development) and country, all of which were expressed as estimated values. Joinpoint regression analysis of the age-standardized incidence of burns from 1990 to 2019 was performed using Joinpoint 4.8.0.1 software to observe the average annual percentage change (AAPC). Rstudio software was used to analyze the Spearman correlation between the age-standardized incidence of burns and SDI from 1990 to 2019. The global inequities of burn incidence were evaluated using the slope index and concentration index from the health equity assessment toolkit, where the slope index reflected the absolute difference in burn incidence between countries with the lowest and highest SDI, and the concentration index indicated the degree to which burn incidence was concentrated in countries with low or high SDI.Results:From 1990 to 2019, the number of global burncases increased from 8 378 121.71 to 8 955 227.68, with an increase of 6.89%. However, the age-standardized incidence rate of burns showed an overall downward trend, from 149.86/100 000 in 1990 to 117.51/100 000 in 2019, with an AAPC of -0.80%. The incidence of burns in the population aged 10-19 years ranked the first in all age groups during the 30 years. Among the six regions of the world, the number of burn cases and the age-standardized incidence rate of burn in the Americas were the highest in 2019, but these two indexes were lower than those in 1999. In 2019, the number of burn patients in medium SDI areas was the highest, and the number of burn patients in low SDI areas was the lowest. The age-standardized incidence of burns was the highest in high SDI areas, and the lowest in medium-low SDI areas. From 1990 to 2019, the number of patients in high and medium-high SDI areas decreased, and the number of patients in other SDI areas increased. Compared with 1990, the age-standardized incidence rates of burns decreased in all SDI regions in 2019, with the greatest decline seen in high SDI and medium-high SDI regions. Cuba had the highest standardized incidence of burns, while Pakistan had the lowest. Spearman correlation analysis showed that from 1990 to 2019, the age-standardized incidence rates of burns in 204 countries and regions were positively correlated with SDI (all P<0.05), and the correlation coefficient decreased from 0.49 in 1990 to 0.37 in 2019. The health inequality slope index decreased from 212.90/100 000 in 1990 to 59.12/100 000 in 2019, and the concentration index decreased from 21.77% in 1990 to 8.38% in 2019. Conclusion:From 1990 to 2019, the global burn incidence rates are disproportionately concentrated in countries and regions with better development status. A significant reduction in the global burn incidence has been accompanied by a significant reduction in these inequities.
8.Effect of Chinese Medicine on Signaling Pathways Related to Hepatocellular Carcinoma and Its Potential Mechanism: A Review
Peirong QIU ; Zeshan CHEN ; Wenlin ZHU ; Peichun PENG ; Jitian WU ; Yulian LI ; Xin DENG
Chinese Journal of Experimental Traditional Medical Formulae 2022;28(23):264-272
Hepatocellular carcinoma (HCC), an insidious malignant tumor with high incidence and lethality, poses a major threat to physical and mental health of human beings. The pathological mechanism needs to be further studied. Surgery, radiotherapy, chemotherapy, and targeted drugs are effective but induce many adverse reactions. Traditional Chinese medicine (TCM) has unique advantages and abundant clinical experience in the treatment of HCC. There has been an explosion of research on the pathways, targets, and mechanism of TCM against HCC from the perspective of molecular biology. According to previous research, Chinese medicinals or compound Chinese medicine prescriptions, directly or indirectly prevent the occurrence and progression of HCC through multiple pathways and targets, which is closely related to the pathophysiological processes such as cell proliferation, metastasis, apoptosis, autophagy, inflammatory response, and immune response. This paper summarizes and analyzes research on the action pathways and mechanisms of Chinese medicine against HCC. Specifically, isoliquiritigenin, dendrobium candidum and Yexiazhu compound Ⅱ regulate phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway to inhibit the growth, proliferation and metastasis of tumor cells. Toad venom and dioscorea zingiberensis induce and enhance HCC autophagy by modulating mammalian target of rapamycin (mTOR) signaling pathway. Myricetin, asparagus, and Biejiajian Wan regulate mitogen-activated protein kinase (MAPK) signaling pathway to promote HCC cell cycle arrest, inhibit angiogenesis, and induce apoptosis. Polygonum odoratum, tetragonum, and plantainoside modulate nuclear factor-kappa B (NF-κB) to inhibit inflammatory response and HCC metastasis and reduce drug resistance. Quercetin and erigeron breviscapus control the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway to suppress epithelial-mesenchymal transition (EMT) and remodel cytoskeleton. This paper is expected to lay a theoretical basis for the in-depth research on and clinical application of Chinese medicine in the treatment of HCC.
9.Research advances in nano-drug delivery system in liver cancer treatment
Miaodong WANG ; Zeshan CHEN ; Peichun PENG ; Xin DENG
Journal of Clinical Hepatology 2022;38(8):1906-1912
Traditional surgical resection, radiotherapy, and chemotherapy still play a dominant role in the treatment of liver cancer; however, their application in liver cancer patients is often limited by the toxic and side effects, unstable efficacy, and unclear targets of chemotherapeutic drugs. Therefore, in order to improve the efficacy of drugs in the treatment of liver cancer, nanomedicine, which has been developed in the biomedical field in recent years, has attracted more and more attention. Nano-drug delivery system has been gradually applied in clinical research for its advantages of low toxicity, wide bioavailability, controllable drug release, and good stability. This article focuses on the latest research advances in nano-drug delivery system in the treatment of liver cancer.
10.Reprogramming Mycobacterium tuberculosis CRISPR System for Gene Editing and Genome-wide RNA Interference Screening
Rahman KHAISTA ; Jamal MUHAMMAD ; Chen XI ; Zhou WEI ; Yang BIN ; Zou YANYAN ; Xu WEIZE ; Lei YINGYING ; Wu CHENGCHAO ; Cao XIAOJIAN ; Tyagi ROHIT ; Naeem Ahsan MUHAMMAD ; Lin DA ; Habib ZESHAN ; Peng NAN ; F.Fu ZHEN ; Cao GANG
Genomics, Proteomics & Bioinformatics 2022;(6):1180-1196
Mycobacterium tuberculosis is the causative agent of tuberculosis(TB),which is still the leading cause of mortality from a single infectious disease worldwide.The development of novel anti-TB drugs and vaccines is severely hampered by the complicated and time-consuming genetic manipulation techniques for M.tuberculosis.Here,we harnessed an endogenous type Ⅲ-A CRISPR/Cas10 system of M.tuberculosis for efficient gene editing and RNA interference(RNAi).This simple and easy method only needs to transform a single mini-CRISPR array plasmid,thus avoiding the introduction of exogenous protein and minimizing proteotoxicity.We demonstrated that M.tuberculosis genes can be efficiently and specifically knocked in/out by this system as con-firmed by DNA high-throughput sequencing.This system was further applied to single-and multiple-gene RNAi.Moreover,we successfully performed genome-wide RNAi screening to identify M.tuberculosis genes regulating in vitro and intracellular growth.This system can be extensively used for exploring the functional genomics of M.tuberculosis and facilitate the development of novel anti-TB drugs and vaccines.